<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">1782</id>
  <title>T3D1778</title>
  <common-name>Bromoacetone</common-name>
  <description>Bromoacetone (C3H5BrO) is an exogenous liquid with an average molecular weight of 136.97 g/mol. Bromoacetone belongs to the carbonyl compounds, a subclass of organooxygen compounds within the organic compounds. Biologically, it functions as a lachrymator and targets the transient receptor potential cation channel subfamily A member 1 (TRPA1).

The compound is found in or released from seven recorded sources, including food contact materials, soap detergents and perfumes within detergents, and electrical and electronic equipment such as hybrid capacitors, television systems, electrodes, and conductors or conductive bodies characterised by the conductive materials. Recorded exposure routes for bromoacetone include oral, touch, and inhalation.</description>
  <cas>598-31-2</cas>
  <pubchem-id>11715</pubchem-id>
  <chemical-formula>C3H5BrO</chemical-formula>
  <weight>135.952380</weight>
  <appearance>Colorless liquid, with a pungent odour. Commercial product is yellow-brown.</appearance>
  <melting-point>-36.5°C</melting-point>
  <boiling-point>137°C</boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral (L626) ; inhalation (L626) ; dermal (L626)</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>Organobromide compounds such as bromoacetone are strong alkylating agents.  Consequently they can readily modify free thiols (cysteines) and methionine residues of the surfaces of proteins leading to the disruption of enzyme, transporter or membrane functions. One of the most probable protein targets is the TRPA1 ion channel that is expressed in sensory nerves (trigeminal nerve) of the eyes, nose, mouth and lungs.

Very effecitve lachrymator at 1.5 mg/m3.</mechanism-of-toxicity>
  <metabolism>Bromoacetone is a metabolic byproduct of bromopropane. It can react with glutathione and generate conjugates that are subsequently secreted in the urine.</metabolism>
  <toxicity>Very effecitve lachrymator at 1.5 mg/m3.</toxicity>
  <lethaldose>Lethal at 3.2 mg/m3 for 10 min.</lethaldose>
  <carcinogenicity>No indication of carcinogenicity (not listed by IARC). (L135)</carcinogenicity>
  <use-source>Bromoacetone is an industrial and laboratory chemical. Occupational exposure to bromoacetone may occur through inhalation and dermal contact with this compound at workplaces where bromoacetone is produced or used.</use-source>
  <min-risk-level></min-risk-level>
  <health-effects>A strong lachrymator. Inhalation, ingestion or skin contact with material may cause severe injury or death.  Animal studies indicate that at very high concentrations it can cause kidney and liver damage. Bromoacetone causes ocular irritation in 30% of human subjects at 0.1 ppm and 100% of human subjects at 1.0 ppm.</health-effects>
  <symptoms>Bromoacetone is a strong lachrymator. Inhalation leads to a burning sensation, cough, sore throat, labored breathing. Skin exposure causes redness, pain. Eyes exposure causes watering of the eyes, redness, pain, blurred vision. Ingestion leads to abdominal pain, burning sensation in the throat and chest, cough, diarrhea, nausea, vomiting.</symptoms>
  <treatment>EYES: irrigate opened eyes for several minutes under running water.
INGESTION: do not induce vomiting. Rinse mouth with water (never give anything by mouth to an unconscious person). Seek immediate medical advice.
SKIN: should be treated immediately by rinsing the affected parts in cold running water for at least 15 minutes, followed by thorough washing with soap and water. If necessary, the person should shower and change contaminated clothing and shoes, and then must seek medical attention.
INHALATION: supply fresh air. If required provide artificial respiration.</treatment>
  <created-at type="dateTime">2009-06-22T16:08:35Z</created-at>
  <updated-at type="dateTime">2026-08-22T12:58:17Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia></wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id></kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>51845</chebi-id>
  <biocyc-id>ACETONE</biocyc-id>
  <ctd-id>C018235</ctd-id>
  <stitch-id>Bromoacetone</stitch-id>
  <drugbank-id></drugbank-id>
  <pdb-id></pdb-id>
  <actor-id></actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CC(=O)CBr</moldb-smiles>
  <moldb-formula>C3H5BrO</moldb-formula>
  <moldb-inchi>InChI=1S/C3H5BrO/c1-3(5)2-4/h2H2,1H3</moldb-inchi>
  <moldb-inchikey>VQFAIAKCILWQPZ-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">136.975</moldb-average-mass>
  <moldb-mono-mass type="decimal">135.952377429</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Liquid</state>
  <logp></logp>
  <hmdb-id></hmdb-id>
  <chembl-id>CHEMBL1085947</chembl-id>
  <chemspider-id>11223</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM001528</chemdb-id>
  <dsstox-id>DTXSID6060507</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00034248</susdat-id>
  <iupac>1-bromopropan-2-one</iupac>
  <moldb-polar-surface-area>17.07</moldb-polar-surface-area>
  <moldb-refractivity>23.9315</moldb-refractivity>
  <moldb-polarizability>9.441421783476619</moldb-polarizability>
  <moldb-rotatable-bond-count>1</moldb-rotatable-bond-count>
  <moldb-acceptor-count>1</moldb-acceptor-count>
  <moldb-donor-count>0</moldb-donor-count>
  <moldb-pka-strongest-acidic>17.79517383275039</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>-7.497037845350995</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>0</moldb-number-of-rings>
  <moldb-alogps-logp>0.38</moldb-alogps-logp>
  <moldb-alogps-logs>-0.74</moldb-alogps-logs>
  <moldb-alogps-solubility>2.49e+01 g/l</moldb-alogps-solubility>
  <kingdom>Organic compounds</kingdom>
  <superklass>Organic oxygen compounds</superklass>
  <klass>Organooxygen compounds</klass>
  <subklass>Carbonyl compounds</subklass>
  <paper-count type="integer">27</paper-count>
  <sync-id>CED0020203</sync-id>
  <structure-inchikey>VQFAIAKCILWQPZ-UHFFFAOYSA-N</structure-inchikey>
  <structure-fingerprint>800000000000000000000000000000000000000000100000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000020000000000000000000800000000000000000010000000000000000000000000000000000000000000000000000400020000040000000000040000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000020000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000400000000000000000000000000000000</structure-fingerprint>
  <structure-pattern-fingerprint>4000000000000000000000000000204000000000040000000040000000000000000000000000000000000000000000400000000c00000000000000000000000000000000000004200000000000000000002000400000000080000200000000000002000000041000000000000100000400011000000001000020040000004000000000000000800001010040002444000000000080000000004004120000000000000000800000000000240000000000000000000000000000000000000040000000000000000000000000000000000400000000000000000000000080000000000000000000000000000000000004000000000020010000000</structure-pattern-fingerprint>
  <structure-pickle type="binary" encoding="base64">776t3gAAAAAQAAAAAwAAAAAAAAAFAAAABAAAAIABBgBgAAAAAQMGACgAAAAD
BAgAKAAAAAMCBgBgAAAAAgIjACAAAAABCwABAAECCAIBAwADBABCAAAAABcE
AAAAAAAAABY=
</structure-pickle>
  <structure-indexed-at type="dateTime">2026-09-19T04:00:11Z</structure-indexed-at>
</compound>
